Galectin Therapeutics reported $11.29M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Gilead Sciences USD 13.04B 9.09B Sep/2026
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Merck USD 10.75B 5.02B Sep/2026